Skip to main content
2022 Annual Clinical Assembly (ACA) Main banner
Final Program


ACA Program Book
Back
Video

Proctology

Treating anal HSIL to prevent anal cancer: results of the ANCHOR Study

Saturday, September 17, 2022
11:00 AM – 12:00 PM East Coast USA Time
Location: 404
CE: 1
Reference 1: Palefsky JM et al. Treatment of anal high-grade squamous intraepithelial lesions to prevent anal cancer. New Engl J Med 2022; 386: 2273-82.
Reference 2: 0
Reference 3: 0

    Non-Member Speaker(s)

  • JP

    Joel Palefsky, MD

    Professor
    UCSF
    UCSF

    Disclosure(s): Antiva Biosciences: Consultant (Ongoing); Merck and Co: Board Member/Advisory Panel (Ongoing); Roche: Board Member/Advisory Panel (Ongoing); Vir Biotechnology: Consultant (Ongoing); Virion Therapeutics: Board Member/Advisory Panel (Ongoing)

    Slides
Disclosure(s):
Joel Palefsky, MD: Antiva Biosciences: Consultant (Ongoing); Merck and Co: Board Member/Advisory Panel (Ongoing); Roche: Board Member/Advisory Panel (Ongoing); Vir Biotechnology: Consultant (Ongoing); Virion Therapeutics: Board Member/Advisory Panel (Ongoing)

Learning Objectives:

  1. Describe the changing epidemiology of anal cancer in the general population and groups at increased risk of anal cancer
  2. Describe results of the ANCHOR study
  3. Describe the recommendations for change in clinical practice resulting from ANCHOR study findings